Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Previous Issue
7th European Myeloma Network Meeting, Prague, 16-18 April 2026
No. 111 (s2)

EMN: Best Abstracts

9
EMN 2026 - Session 1. Biology and preclinical

B01 | TIME-RESOLVED MULTI-LAYERED PROFILING IDENTIFIES RESOLUTION OF RIBOSOME COLLISIONS AND TRANSLATIONAL RECOVERY AS MECHANISMS CONTRIBUTING TO PROTEASOME INHIBITOR RESISTANCE (156 Online Views)

J. Zhou1, N.T. Crump1, M. Román-Trufero1|2, H.W. Auner1|2|3

1 Department of Immunology and Inflammation, Imperial College London, UK
2 Division of Haematology and Central Haematology Laboratory, Lausanne University Hospital, Switzerland
3 Faculty of Biology and Medicine, University of Lausanne, Switzerland
Proteasome Inhibitor Resistance Carfilzomib Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14067
EMN 2026 - Session 4. Special conditions

B02 | THE PROGNOSTIC IMPACT OF BONE MARROW PLASMA CELL INFILTRATION AT DIAGNOSIS IN AL AMYLOIDOSIS (123 Online Views)

K. Aslantaş1, Ş. Özlü2, I. Kuzu2, M. Beksaç3|4, G. Cengiz Seval4

1 Department of Internal Medicine, Ankara University Faculty of Medicine, Turkey
2 Department of Pathology, Ankara University Faculty of Medicine, Turkey
3 Istinye University, Ankara Liv Hospital, Turkey
4 Department of Hematology, Ankara University Faculty of Medicine, Turkey
AL amyloidosis BMPC Turkey
https://doi.org/10.3324/haematol.2026.s2.14048
EMN 2026 - Session 1. Biology and preclinical

B03 | TRANSCRIPTOMIC PROFILING OF CIRCULATING TUMOR CELLS (CTCS) IN MULTIPLE MYELOMA REVEALS EGRESSION-ASSOCIATED PROFILE RELATED TO CTC BURDEN (121 Online Views)

D. Bilek1|2|3, E. Radova2|3, V. Kapustova1|2, M. Warmuzova1|2, O. Venglar1|2, S. Nenarokov1|2, L. Broskevicova1|2, J. Vrana1|2, M. Kudelkova1|2, L. Muronova1|2, T. Popkova1|2, J. Mihalyova1|2, H. Plonkova4, M. Durante4, B. Diamond4, M. Simicek1|2, J. Bago1|2, D. Zihala1|2|3, T. Sevcikova1|2|3, O. Landgren4, R. Hajek1|2, T. Jelinek1|2|4

1 Department of Hemato-oncology, University Hospital Ostrava, Czech Republic
2 Department of Hemato-oncology, Faculty of Medicine, University of Ostrava, Czech Republic
3 Department of Biology and Ecology, Faculty of Science, University of Ostrava, Czech Republic
4 Sylvester Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, USA
Circulating Tumor Cells NDMM New Prognostic Factors.
https://doi.org/10.3324/haematol.2026.s2.14074
EMN 2026 - Session 2. Newly diagnosed multiple myeloma

B04 | BLOOD-BASED RISK STRATIFICATION OF MYELOMA PATIENTS USING CIRCULATING TUMOR CELLS: RESULTS FROM THE EUROPEAN CTC CONSORTIUM (130 Online Views)

L. Bertamini1, D. Zihala2, I.V. Kostopoulos3, M. D’Agostino4, E. Martín-Sánchez5, J.J. Garcés Latre5, D. Hofste Op Bruinink1, N. Puig6, S. Zweegman7, G. Bertuglia4, P. Malandrakis8, T. Sevcikova2, T. Cupedo1, N.W.C.J. Van De Donk7, M.T. Cedena9, P. Musto10, I. Ntanasis-Stathopoulos8, O. Venglar2, M. Van Duin1, J.J. Lahuerta9, D. Rota Scalabrini11, O. Tsitsilonis3, T. Popkova2, J. Blade12, E. Zamagni13, M. Gavriatopoulou8, L. Muronova2, B. Van Der Holt1|14, P.. Moreau15, M.V. Mateos6, M. Galli16, E. Katodritou17, M. Stork18, A. Belotti19, P. Rousakis3, M. Borsky18, J. Corre20, M. Boccadoro21, M. Dimopoulos8, R. Hajek2, J. San Miguel5, P. Sonneveld1, F. Gay4, E. Terpos8, A. Broijl1, B. Paiva3, T. Jelinek2

1 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
2 Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Czech Republic
3 Department of Biology, School of Science, National and Kapodistrian University of Athens, Greece
4 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy
5 Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
6 Hospital Universitario,Salamanca, Spain
7 Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, the Netherlands
8 Department of Clinical Therapeutics School of Medicine, National and Kapodistrian University of Athens, Greece
9 Hospital Universitario 12 De Octubre, Madrid, Spain
10 Department of Precision and Regenerative Medicine and Ionian Area,"Aldo Moro" University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy
11 Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Torino, Italy
12 Hospital Clínic de Barcelona, Spain
13 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy
14 HOVON Foundation, Rotterdam, the Netherlands
15 Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
16 Hematology and Bone Marrow Transplant Unit, Azienda Socio-Sanitaria Territoriale-Papa Giovanni XXIII, Bergamo, Italy
17 Department of Hematology, Theageneio Cancer Hospital, Thessaloniki, Greece
18 Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic
19 Department of Hematology, ASST Spedali Civili di Brescia, Italy
20 Unité de Génomique du Myélome, University Hospital, IUCT-Oncopole, CRCT, Toulouse, France
21 European Myeloma Network, EMN
Circulating Tumor Cells Multiple Myeloma Plasma Cell Egression.
https://doi.org/10.3324/haematol.2026.s2.14103
EMN 2026 - Session 4. Special conditions

B05 | SPATIAL IMAGING UNLOCKS THE POTENTIAL OF CHARTING MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE (106 Online Views)

V. Desantis1, A. Andriano1, G. De Martino1, T. Düking2, O. Hartwig2, G. Ingravallo3, M. Biondo3, C. Botta4, R. Ria5, A. Vacca5, A.G. Solimando5

1 Department of Precision and Regenerative Medicine and Ionian Area-DiMePRe-J, Section of Pharmacology, University of Bari Aldo Moro, Italy
2 Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany
3 Department of General Surgery and Medical-Surgical Specialties, University of Catania, Italy
4 Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Italy
5 Internal Medicine "Guido Baccelli", University of Bari Aldo Moro, Italy
Spatial Imaging Plasma Cell Subclones Multiple Myeloma.
https://doi.org/10.3324/haematol.2026.s2.14091
EMN 2026 - Session 2. Newly diagnosed multiple myeloma

B06 | BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE/DEXAMETHASONE IN NEWLY DIAGNOSED INTERMEDIATE-FIT AND FRAIL MULTIPLE MYELOMA: LONG-TERM EFFICACY AND SAFETY FROM THE PHASE 1/2 BELARD CLINICAL TRIAL (110 Online Views)

E. Terpos1, M. Gavriatopoulou1, I.N. Stathopoulos1, P. Malandrakis1, N. Kanellias1, M. Migkou1, F. Theodorakakou1, E. Solia1, E.E. Papaiakovou1, E. Kastritis1, M.A. Dimopoulos1|2

1 National and Kapodistrian University of Athens, Greece
2 Korea University, Seoul, South Korea
Newly diagnosed myeloma BelaRd trial Durable Disease Control.
https://doi.org/10.3324/haematol.2026.s2.14094
EMN 2026 - Session 3. Relapsed/refractory multiple myeloma

B07 | PROGNOSTIC ROLE OF STANDARDIZED (18)F-FDG-PET/CT AND WB-DW-MRI IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING T CELL-REDIRECTING THERAPIES (143 Online Views)

M. Talarico1|2, A. Cattabriga1|3, L. Pagnini1|4, V. Solli1|2, S. Barbato1|2, S. Ghibellini1|2, S. Masci1|2, E. Manzato1|2, M. Puppi1|2, M. Iezza1|2, K. Mancuso1|2, L. Pantani2, P. Tacchetti2, C. Terragna2, M. Ursi5, E. Maffini5, F. Bonifazi5, S. Brocchi3, C. Mosconi1|3, C. Nanni4, S. Fanti1|4, E. Zamagni1|2

1 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
2 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
3 Department of Radiology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
4 Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
5 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
RRMM Functional Imaging T-cell Therapy
https://doi.org/10.3324/haematol.2026.s2.14047
EMN 2026 - Session 4. Special conditions

B09 | DARATUMUMAB MONOTHERAPY VS. ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE (122 Online Views)

F. Schjesvold1, P.M. Voorhees2, M.A. Dimopoulos3, Y.C. Cohen4, V. Hungria5, I. Sandhu6, J. Lindsay7, R.I. Baker8, K. Suzuki9, H. Kosugi10, M-D. Levin11, M. Beksac12, K. Stockerl-Goldstein13, H. Magen4, A. Oriol14|15, G. Mikala16, G. Garate17, K. Theunissen18, I. Spicka19, A.K. Mylin20, S. Hallam21, S. Bringhen22, K. Uttervall23, B. Pula24, A.M. Khan25, E. Medvedova26, J.C. Ye27, A.J. Cowan28, P.. Moreau29, M-V. Mateos30, H. Goldschmidt31, D. Vieyra32, A. Raval32, L. Sha32, L. Li32, E. Rousseau32, R.M. Dennis32, R.L. Carson32, S.V. Rajkumar33

1 University of Oslo, Norway
2 Wake Forest University School of Medicine, Charlotte, USA
3 National and Kapodistrian University of Athens, Greece
4 Tel Aviv University, Israel
5 Clinica Médica São Germano, São Paulo, Brazil
6 Cross Cancer Institute, Edmonton, Canada
7 Kent and Canterbury Hospital, Canterbury, UK
8 Murdoch University, Perth, Australia
9 Japanese Red Cross Medical Center, Tokyo, Japan
10 Ogaki Municipal Hospital, Japan
11 Albert Schweitzer Hospital, Dordrecht, The Netherlands
12 Ankara University, Turkey
13 Washington University School of Medicine, St. Louis, USA
14 Hospital Germans Trias i Pujol
15 , Badalona, Spain
16 South Pest Central Hospital, Budapest, Hungary
17 Hospital Alemán, Buenos Aires, Argentina
18 Jessa Hospital, Hasselt, Belgium
19 Charles University, Prague, Czech Republic
20 University of Copenhagen, Denmark
21 Queen Mary University of London, UK
22 AOU Città della Salute e della Scienza di Torino, Italy
23 Karolinska University Hospital, Stockholm, Sweden
24 Institute of Hematology and Transfusion Medicine, Warsaw, Poland
25 The Ohio State University Comprehensive Cancer Center, Columbus, USA
26 Oregon Health and Science University, Portland, USA
27 University of Texas, Houston, USA
28 University of Washington, Seattle, USA
29 University Hospital Hôtel-Dieu, Nantes, France
30 University Hospital of Salamanca, Spain
31 Heidelberg University Hospital, Germany
32 Johnson & Johnson
33 Mayo Clinic, Rochester, USA
Smoldering Multiple Myeloma AQUILA study Daratumumab.
https://doi.org/10.3324/haematol.2026.s2.14042
EMN 2026 - Session 3. Relapsed/refractory multiple myeloma

B10 | HEPTA-REFRACTORY MULTIPLE MYELOMA: BIOLOGY, PROGNOSIS, AND TREATMENT (126 Online Views)

C. Riedhammer1, M. Truger2, H. Lee3, L.B. Leypoldt4|5, M. Meggendorfer2, S. Hutter2, H. Müller2, J. Mersi1, S.K. Kadel1, T. Buchwald1, R. Kosch4, M. Helal6, N. Afrin6, A. Rosenwald7, E. Gerhard-Hartmann7, A. Brioli8|9, J. Krönke8, T. Haferlach2, C. Haferlach2, K.C. Weisel4, P. Neri3, H. Einsele1, K.M. Kortüm1, J.M. Waldschmidt1, N. Bahlis3, N. Weinhold10|11, L. Rasche1|6

1 Department of Internal Medicine 2, University Hospital of Würzburg, Germany
2 MLL Munich Leukemia Laboratory, Germany
3 Arnie Charbonneau Cancer Institute, University of Calgary, Canada
4 Department of Hematology, Oncology and Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Germany
5 Mildred Scheel Early Career Center, University Medical Center Hamburg-Eppendorf, Germany
6 Mildred Scheel Early Career Center, University Hospital Würzburg, Germany
7 Institute of Pathology, University of Würzburg, Germany
8 Department of Internal Medicine C, University Hospital of Greifswald, Germany
9 Hannover Medical School, Clinic for Hematology, Hemostaseology, Oncology and Stem Cell Transplantation, Germany
10 Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Germany
11 Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center, Germany
Multiple myeloma Hepta-refractory Immunotherapy.
https://doi.org/10.3324/haematol.2026.s2.14087

EMN: Posters

73
EMN 2026 - Session 1. Biology and preclinical

P01 | CIRCULATING TUMOR CELLS IMPROVE RISK STRATIFICATION ACCORDING TO THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM AND THE IMS-IMWG CONSENSUS GENOMIC STAGING IN NDMM PATIENTS. AN ANALYSIS FROM THE EUROPEAN CTC CONSORTIUM (84 Online Views)

M. D’Agostino1, E. Martín-Sánchez2, D. Žihala3|4, I. Kostopoulos5, J.J. Garcés6, N. Puig7, G. Bertuglia1, T. Ševčíková3, T. Cupedo8, M. Van Duin8, J. Keats9, E. Zamagni10|11, P. Moreau12, S. Zweegman13, B. Van Der Holt8|14, D. Hofste Op Bruinink8, E. Dama15, J. Corre16, M. Boccadoro15, M.A. Dimopoulos17|18, R. Hájek3|4, B. Paiva2, P. Sonneveld8|19, A. Broijl8, E. Terpos17, T. Jelínek3|4, J. San-Miguel2, F. Gay1, L. Bertamini8

1 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy
2 Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain
3 Department of Hematooncology, University Hospital Ostrava, Czech Republic
4 Department of Hematooncology, Faculty of Medicine, University of Ostrava, Czech Republic
5 School of Science, National and Kapodistrian University of Athens, Greece
6 Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, USA
7 Hospital Universitario Salamanca, Spain
8 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
9 Clinical Genomics and Therapeutics Division, Translational Genomics Research Institute, Phoenix, USA
10 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Italy
11 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
12 Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
13 Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit, The Netherlands
14 HOVON Foundation, Rotterdam, The Netherlands
15 European Myeloma Network, Italy
16 Unité de Génomique du Myélome, University Hospital, IUCT-Oncopole, CRCT, Toulouse, France
17 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece
18 Department of Medicine, Korea University, Seoul, Korea
19 European Myeloma Network, The Netherlands
Circulating Tumor Plasma Cells NDMM European CTC Consortium.
https://doi.org/10.3324/haematol.2026.s2.14064

P02 | INTERACTION BETWEEN MYELOMA AND BONE MARROW MESENCHYMAL STEM CELLS (107 Online Views)

H. Ahmed1|2, J. Vorwerk2, M. Hussein2, P.K. Patnana1|2, A.K. Rout3, U. Guenther3, N. Von Bubnoff2, W. Mansour4, C. Khandanpour1|2

1 Department of Internal Medicine, Hematology and Oncology, University Medicine Oldenburg, Germany
2 Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, University of Lübeck, Germany and Universitäres Cancer Center Schleswig-Holstein, Germany
3 Institute of Chemistry and Metabolomics, University of Lübeck, Germany
4 University Medical Center Hamburg-Eppendorf, Oncology Center, Department for Radiotherapy and Radio-Oncology, Germany
Multiple Myeloma Mesenchymal Stromal Cells Responde to Therapy.
https://doi.org/10.3324/haematol.2026.s2.14104

P03 | BONE MARROW MICROENVIRONMENT-DEPENDENT INDUCTION OF mTORC1 CAUSES THERAPY RESISTANCE IN MULTIPLE MYELOMA (99 Online Views)

M.H. Janssens1, G. De Wilde1, M. Spaargaren1, R.W. Groen2, J.E.J. Guikema1

1 Pathology, Amsterdam UMC, The Netherlands
2 Hematology, Amsterdam UMC, The Netherlands
mTORC1 FOXO transcription factors Rapamycin.
https://doi.org/10.3324/haematol.2026.s2.14107

P04 | DEVELOPMENT OF A NEW 3D EX-VIVO MODEL FOR MULTIPLE MYELOMA (93 Online Views)

M. Domingos1|2, E. Carneiro2, A. Queirós2, C. João2|3|4

1 Bioengineering Department, Instituto Superior Técnico, Lisbon, Portugal
2 Myeloma and Lymphoma Research Group, Champalimaud Research Center, Lisbon, Portugal
3 Hemato-Oncology Unit, Champalimaud Clinical Centre, Lisbon, Portugal
4 NOVA Medical School, NOVA University, Lisbon, Portugal
Multiple Myeloma 3D model Culture Platform.
https://doi.org/10.3324/haematol.2026.s2.14071

P05 | ZEBULARINE MODULATES DNA METHYLTRANSFERASE EXPRESSION THROUGH ASSOCIATED HISTONE COMPLEXES AT THEIR PROMOTERS IN MULTIPLE MYELOMA CELL LINES (110 Online Views)

L. Slavíčková1, D. Švehlová1, J. Minarik2|3, K. Smešný Trtková1|4|5

1 Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, University Palacky Olomouc, Czech Republic
2 Department of Hemato-oncology, Faculty of Medicine and Dentistry, University Palacky Olomouc, Czech Republic
3 Department of Hemato-oncology, University Hospital Olomouc, Czech Republic
4 Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, University Palacky Olomouc, Czech Republic
5 Department of Clinical and Molecular Pathology and Medical Genetics, Faculty of Medicine, University of Ostrava, Czech Republic
Zebularine DNA methylation Multiple Myeloma.
https://doi.org/10.3324/haematol.2026.s2.14080

P06 | FROM BENCH TO BEDSIDE: DRUG SENSITIVITY PROFILING TO OPTIMIZE THERAPY IN RELAPSED MULTIPLE MYELOMA (105 Online Views)

R. Cassano Cassano1|2, T. Martins3, D. Coffey4, G. Buda5, S. Galimberti5, L.M.A. Melillo2, R. Donnelly1, M. Kwok1, D. Green1, R. Banerjee1, K. Cicero1, T. Gooley1, R. Silbermann4, P. Becker6, A.J. Cowan1, D. Dima1

1 Fred Hutchinson Cancer Center, Seattle, USA
2 Policlinico Riuniti Foggia, Hematology Division, Italy
3 University of Washington, Seattle, USA
4 University of Miami Hospital and Clinics-UHealth Tower, USA
5 University of Pisa, Italy
6 OHSU Hospital, Portland, USA
Relapsed Multiple Myeloma CART Drug Sensitivity
https://doi.org/10.3324/haematol.2026.s2.14100

P07 | CYTOKINE AND BONE MICROENVIRONMENT PROFILES REFLECT DISEASE STAGE AND OSTEOLYTIC INVOLVEMENT IN MULTIPLE MYELOMA (86 Online Views)

J. Minarik1, J. Proskova2, V. Latal1, P. Krhovska1, T. Pika1

1 Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
2 Department of Clinical Biochemistry Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
Multiple Myeloma Osteolytic Involvement
https://doi.org/10.3324/haematol.2026.s2.14033

P08 | MODULATION OF miR-29b EXPRESSION AND APOPTOSIS IN MULTIPLE MYELOMA CELL LINES FOLLOWING TREATMENT WITH HALF-SANDWICH OS(II) COMPLEXES (107 Online Views)

D. Švehlová1, L. Slavíčková1, I. Frydrych2, P. Štarha3, K. Smešný Trtková1|2|4

1 Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
2 Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
3 Department of Inorganic Chemistry, Faculty of Science, Palacky University, Olomouc, Czech Republic
4 Department of Clinical and Molecular Pathology and Medical Genetics, Faculty of Medicine, University of Ostrava, Czech Republic
miR-29b Expression Multiple Myeloma Pro-apoptotic Effects
https://doi.org/10.3324/haematol.2026.s2.14081
EMN 2026 - Session 2. Newly diagnosed multiple myeloma

P10 | HIGH ACCURACY OF NEXT-GENERATION FLOW IN PREDICTING MEASURABLE RESIDUAL DISEASE BY NEXT-GENERATION SEQUENCING IN THE 10⁻⁶ RANGE: A PROSPECTIVE COMPARISON WITHIN THE PHASE III EMN24 ISKIA TRIAL (108 Online Views)

M. D'Agostino1, M. Van Duin2, W. Roeloffzen3, M.A. Dimopoulos4|5, L. Rosiñol6, M. Van Der Klift7, J. Martínez-López8, A. Oriol9, E. Katodritou10, K.L. Wu11, P. Rodríguez Otero12, R. Hájek13|14, E. Dama15, D. Oddolo15, G. Gazzera15, E.M. Van Leeuwen-Segarceanu16|17, N.W.C.J. Van De Donk18, S. De Jonge-Peeters19, T.S. Slørdahl20, J. Straub21, M. Westerman22, F. Schjesvold23|24, J. Bladé6, H. Einsele25, M. Boccadoro15, P. Sonneveld2|26, A. Broijl2, F. Gay1

1 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy
2 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
3 Department of Hematology, University Medical Center Groningen, The Netherlands
4 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece
5 Department of Medicine, Korea University, Seoul, Korea
6 Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic de Barcelona, IDIBAPS and PETHEMA/GEM, Spain
7 Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands
8 Hematology Department, Hospital Universitario de Octubre, Medicine Department Complutense University, imas12, CNIO, Madrid, Spain
9 Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain
10 Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece
11 ZNA Cadix, Antwerp, Belgium
12 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
13 Department of Haematooncology, University Hospital Ostrava, Czech Republic
14 Department of Haematooncology, Faculty of Medicine, University of Ostrava, Czech Republic
15 European Myeloma Network, Italy
16 Department of Hematology, St. Antonius Hospital
17 Nieuwegein, The Netherlands
18 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, The Netherlands
19 Department of Hematology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
20 Department of Hematology, St. Olavs University Hospital, Trondheim, Norway
21 Internal Medicine, Hematology Clinic, General University Hospital, Prague, Czech Republic
22 Northwest Clinics, Alkmaar, The Netherlands
23 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Sweden
24 KG Jebsen Center for B cell malignancies, University of Oslo, Sweden
25 Department of Internal Medicine II, University Hospital Würzburg, Germany
26 European Myeloma Network, The Netherlands
Multiple Myeloma Measurable residual disease IsaKRd trial
https://doi.org/10.3324/haematol.2026.s2.14063

P11 | PERIPHERAL MEASURABLE RESIDUAL DISEASE ACTIVITY ASSESSMENT BY MALDI-TOF MASS SPECTROMETRY IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA IN THE PHASE 3 GMMG-HD7 TRIAL (78 Online Views)

J.X. Jin1, V.R. Ginde2, S. Huhn1|3, P.. Reichert1|3, U. Bertsch1|3, R. Fenk4, B. Besemer5, A. Boquoi6, R. Schroers7, I. Von Metzler8, M. Hänel9, C.. Mann10, L.B. Leypoldt11, B. Heilmeier12, C. Scheid13, T. Peters-Regehr14, I.W. Blau15, C. Müller-Tidow1, S. Luntz16, T.A.W. Holderried17, K. Trautmann-Grill18, D. Gezer19, M. Klaiber-Hakimi20, M. Müller21, E. Shumilov22, W. Knauf23, C.S. Michel24, T. Geer25, H. Riesenberg26, C.. Lutz27, M.S. Raab1, N. Weinhold1, M. Hoffmann28, A. Benner2, P. Findeisen29, K.C. Weisel11, H.J. Salwender30, H. Goldschmidt1|3, E.K. Mai1

1 Heidelberg Myeloma Center, Internal Medicine V, Hematology, Oncology and Rheumatology, and German-speaking Myeloma Multicenter Group GMMG, Heidelberg University Hospital and Medical Faculty Heidelberg, Germany
2 Division of Biostatistics, German Cancer Research Center
3 National Center for Tumor Diseases Heidelberg, Germany
4 Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Germany
5 Department of Internal Medicine II, University Hospital Tübingen, Germany
6 Department for Hematology and Stem Cell Transplantation, University Hospital Essen, Germany
7 Department of Hematology and Oncology, Knappschaft Kliniken, Ruhr-University Bochum, Germany
8 Department of Medicine II-Hematology and Oncology, Goethe-University Frankfurt, University Hospital, Frankfurt am Main, Germany
9 Department of Internal Medicine III, Klinikum Chemnitz, Germany
10 Department for Hematology, Oncology and Immunology, University Hospital Giessen and Marburg, Marburg, Germany
11 Department of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
12 Clinic for Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, Germany
13 Department of Internal Medicine I, University Hospital Cologne, Germany
14 The Binding Site GmbH, part of Thermo Fisher Scientific, Schwetzingen, Germany
15 Medical Clinic, Charité University Medicine Berlin, Germany
16 Coordination Centre for Clinical Trials-KKS, University Hospital and Medical Faculty Heidelberg, Germany
17 Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Germany
18 Department of Internal Medicine I, University Hospital Dresden, Germany
19 Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Germany
20 Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Germany
21 Clinic for Hematology, Oncology and Immunology, Klinikum Siloah Hannover, Germany
22 Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Germany
23 Center for Hematology and Oncology Bethanien, Frankfurt am Main, Germany
24 Department of Internal Medicine III, University Hospital Mainz, Germany
25 Department of Internal Medicine III, Diakoneo Clinic Schwäbisch-Hall, Schwäbisch-Hall, Germany
26 Hematology/Oncology Center, Bielefeld, Germany
27 Hematology/Oncology Center, Koblenz, Germany
28 Medical Clinic A, Clinic Ludwigshafen, Germany
29 MVZ Labor Dr. Limbach und Kollegen, Heidelberg, Germany
30 Asklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Germany. °For The German-Speaking Myeloma Multicenter Group. *Contributed equally as senior authors. *Hd7 Investigators
MALDI-TOF Minimal Residual Disease Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14035

P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE (86 Online Views)

P. Sonneveld1, P.. Moreau2, H. Einsele3, H. Quach4, P.J. Ho5, M. Beksac6, C. Hulin7, E. Antonioli8, X. Leleu9, S. Mangiacavalli10, A. Perrot11, M. Cavo12, A. Belotti13, A. Broijl1, H. Pei14, A. Sitthi-Amorn14, R.L. Carson14, P. Rodríguez-Otero15, M.A. Dimopoulos16, M. Boccadoro17

1 Erasmus MC Cancer Institute, Rotterdam, The Netherlands
2 University Hospital Hôtel-Dieu, Nantes, France
3 Universitätsklinikum Würzburg, Germany
4 University of Melbourne, Australia
5 Royal Prince Alfred Hospital, Sydney, Australia
6 Ankara University, Turkey
7 Hôpital Haut Lévêque, Pessac, France
8 University of Florence, Italy
9 CHU Poitiers, France
10 University of Pavia, Italy
11 Centre Hospitalier Universitaire de Toulouse, France
12 Bologna University, Italy
13 ASST Spedali Civili di Brescia, Italy
14 Johnson & Johnson, USA
15 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
16 National and Kapodistrian University of Athens, Greece
17 University of Turin, Italy
Minimal residual disease NDMM Therapy
https://doi.org/10.3324/haematol.2026.s2.14037

P13 | ISATUXIMAB WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOLLOWED BY ISATUXIMAB AND LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT: FINAL ANALYSIS OF A PHASE 2 STUDY BY GREEK MYELOMA STUDY GROUP (85 Online Views)

E. Terpos1, E. Kastritis1, S. Delimpasi2, K. Papathanasiou3, V. Labropoulou4, N. Kanellias1, I.N. Stathopoulos1, M. Migkou1, E. Solia1, F. Theodorakakou1, E.E. Papaiakovou1, M. Kotsopoulou5, E. Katodritou6, M. Gavriatopoulou1, M.A. Dimopoulos1|7

1 National and Kapodistrian University of Athens, Greece
2 Evangelismos Hospital, Athens, Greece
3 University of Ioannina, Greece
4 University of Patras, Medical School, Greece
5 Metaxa Cancer Hospital,Piraeus, Greece
6 Theagenio Cancer Hospital, Thessaloniki, Greece
7 Korea University, Seoul, South Korea
Greek Myeloma Study Group NDMM Isa-VRd
https://doi.org/10.3324/haematol.2026.s2.14108

P14 | DARATUMUMAB-BORTEZOMIB-MELPHALAN-PREDNISONE VS. DARATUMUMAB-LENALIDOMIDE-DEXAMETHASONE IN TRANSPLANT-INELIGIBLE REAL-LIFE PATIENTS WITH MULTIPLE MYELOMA: A SUBANALYSIS OF THE PHASE IV REAL MM TRIAL (97 Online Views)

L. Cani1, S. Bringhen2|3, A. Piciocchi4, N. Giuliani5|6, S. Mangiacavalli7, A.P. Falcone8, G. Benevolo1, M. Capriata9, F. Vassallo2, F. Ciceri10, F. Pane11, R. Floris12, M. Cantonetti13, S. Pezzatti14, M. D'Agostino1, A. Casson1, A. Evangelista15, E. Saraci16, M. Mirabile17, B. Gamberi18, A. Conconi19, G. Pietrantuono20, P. Galieni21, P. Curci22, G. Margiotta-Casaluci23, A. Liso24|25, M. Scaldaferri26, B. Bruno1, M. Boccadoro27, A. Larocca1

1 Division of Hematology, AOU Città della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy
2 S. C. Ematologia, Azienda Ospedaliera Santa Croce e Carle, Cuneo, Italy
3 SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Department of Oncology, AOU Città della Salute e della Scienza di Torino, University of Turin, Italy
4 GIMEMA Foundation, Rome, Italy
5 Department of Medicine and Surgery, University of Parma
6 Hematology, Department of Hemato-Oncology, AOU Parma, Italy
7 Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
8 Hematology, IRCCS "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo, Italy
9 Haematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Italy
10 U. O. Ematologia e Trapianto di Midollo, IRCCS Ospedale San Raffaele, Milan, Italy
11 Hematology Unit, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Italy
12 S. C. Ematologia e CTMO, Ospedale Oncologico “A. Businco”, Cagliari, Italy
13 Hematology Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata
14 Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
15 Unit of Clinical Epidemiology, AOU Città della Salute e della Scienza di Torino and CPO Piemonte, Italy
16 University of Torino and Department of Molecular Biotechnology and Health Sciences, Italy
17 Hematology Unit, Ospedale di Civitanova Marche, ASUR AV3 Italy
18 Azienda USL - IRCCS di Reggio Emilia, Italy
19 Division of Hematology, Department of Medicine, Ospedale degli Infermi, Biella, Italy
20 Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy
21 UOC Ematologia e Terapia cellulare, Ospedale C. e G. Mazzoni, Ascoli Piceno, Italy
22 Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari, Italy
23 Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale/AOU Maggiore della Carità di Novara, Italy
24 Department of Medicine and Surgery, University of Perugia, Italy
25 Hematology/Oncology Unit, Terni Hospital, Italy
26 SC Farmacia Ospedaliera, AOU Città della Salute e della Scienza di Torino, Italy
27 European Myeloma Network, Italy
REAL MM Trial Measurable Residual Disease Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14052

P15 | RANDOMIZED COMPARISON OF ISATUXIMAB–RD INDUCTION FOLLOWED BY ISA R MAINTENANCE VS. RD INDUCTION FOLLOWED BY R MAINTENANCE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (AGMT MM04 TRIAL) (95 Online Views)

H. Ludwig1, T. Melchardt2, E. Terpos3, J. Bila4, M. Schreder5, S. Bernhard1, K. Podar6, E. Katodritou7, T. Sliwa8, P. Djurdjevic9, S. Delimpasi10, M. Leisch2, M. Mitrovic4, M. Gavriatopoulou3, I. Ntanasis-Stathopoulos3, E.M. Autzinger11, A. Zabernigg12, M. Fillitz13, E. Wöll14, P. Pichler15, I.M. Sáenz De Tejada16|17|18, B. Paiva16|17|18, R. Greil19|20|21|22|23|24|25

1 Wilhelminen Cancer Research Institute, First Department of Medicine, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria
2 Department of Internal Medicine III With Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, Vienna, Austria
3 Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Greece
4 Clinic of the Hematology, University Clinical Center of Serbia, Belgrade, Serbia
5 First Department of Medicine, Center for Oncology, Hematology, and Palliative Care, Clinic Ottakring, Vienna, Austria
6 Division of Internal Medicine 2, University Hospital Krems, Krems an der Donau, Austria
7 Department of Haematology, Theagenion Anticancer General Hospital, Thessaloniki, Greece
8 Department of Hemato-Oncology, LKH Hochsteiermark-Leoben, Austria
9 Clinic of Hematology, University Clinical Center of Kragujevac, Serbia
10 Hematology, Evangelismos Hospital, Athens, Greece
11 First Department of Medicine, Hematology and Oncology, Hospital Barmherzige Schwestern, Vienna, Austria
12 Department of Internal Medicine, County Hospital Kufstein, Austria
13 Department of Internal Medicine, Hanusch Krankenhaus, Vienna, Austria
14 Department of Internal Medicine, St. Vinzenz Hospital, Zams, Austria
15 Department of Internal Medicine, University Hospital of St. Pölten, Austria
16 Clínica Universidad de Navarra, Centro de Investigaciones Biomédicas Aplicadas
17 (CIMA), Instituto de Investigación Sanitaria de Navarra
18 (IdiSNA), Pamplona, Spain
19 Austrian Group for Medical Tumor Therapy
20 (AGMT)GmbH, Salzburg, Austria
21 Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research
22 (SCRI-LIMCR), Austria
23 Salzburg Cancer Research Institute-Center for Clinical Cancer and Immunology Trials
24 (SCRI-CCCIT)GmbH, Austria
25 Cancer Cluster Salzburg, Austria
NDMM Isa-Rd Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14093

P16 | INTEGRATED p53 ISOFORM EXPRESSION DEFINES NOVEL PROGNOSTIC SUBGROUPS IN MULTIPLE MYELOMA (111 Online Views)

E. Borsi1, A. Vitale2, V. Solli2, V. Meixian Vuong2, M. Martello1, I. Vigliotta1, S. Armuzzi2, A. Poletti2, B. Taurisano2, A. Varacalli1|2, G. Mazzocchetti2, A. Croce2, I. Pistis1, E. Zamagni2|1, P. Tacchetti1, I. Rizzello1|2, M. Cavo2, C. Terragna1

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
2 DIMEC – Dipartimento di Medicina e Chirurgia, Università di Bologna, Italy
p53 isoform Multiple Myeloma Prognostic Factors
https://doi.org/10.3324/haematol.2026.s2.14089

P17 | EARLY TREATMENT RESPONSE EVALUATION WITH WHOLE BODY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND FOCAL LESIONS (101 Online Views)

I. Ntanasis-Stathopoulos1, V. Koutoulidis2, M. Gavriatopoulou1, M. Douka2, P. Malandrakis1, C. Filippatos1, V. Spiliopoulou1, F. Theodorakakou1, I. Katsadouros1, I. Solia1, P. Boutsikos1, M. Migkou1, N. Kanellias1, E. Eleutherakis-Papaiakovou1, E. Kastritis1, L.A. Moulopoulos2, M.A. Dimopoulos1|3, E. Terpos1

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece
2 1st Department of Radiology, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens, Greece
3 Department of Medicine, Korea University, Seoul, South Korea
Whole-body magnetic resonance imaging NDMM Early response
https://doi.org/10.3324/haematol.2026.s2.14034

P18 | MONOCLONAL AND POLYCLONAL CIRCULATING PLASMA CELLS ARE ASSOCIATED WITH DISEASE DISSEMINATION IN MULTIPLE MYELOMA (105 Online Views)

I. Vigliotta1, A. Varacalli1, M. Talarico1|2, V. Solli2, B. Taurisano2, S. Armuzzi2, I. Pistis1, V.M. Vuong2, A. Vitale1, G. Mazzocchetti3|4, E. Borsi1, A. Croce2, M. Martello1, A. Poletti2, C. Nanni5, K. Mancuso1|2, M. Puppi1|2, M. Cavo2, E. Zamagni1|2, C. Terragna1

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy
2 Department of Medical and Surgical Sciences - University of Bologna, Italy
3 FABIT-Department of Pharmacy and Biotechnology, University of Bologna, Italy
4 Computational and Chemical Biology, Italian Institute of Technology, CMP3VdA, Aosta, Italy
5 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Nuclear Medicine, Bologna, Italy
Circulating Plasma Cells Multiple Myeloma NDMM
https://doi.org/10.3324/haematol.2026.s2.14082

P20 | INFLAMMATION SCORE (I-SCORE) IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA: A NEW EASY TOOL TO ASSESS PROGNOSIS (94 Online Views)

V. Bongarzoni1, B. Anaclerico1, G. Tomei2, S. Morè3, F. Di Landro4, F. Fazio5, F. Fioritoni6, G. Antolino7, S. Gentili8, L. De Padua9, L. Cupelli10, S. Gumenyuk11, M. Di Cecca12, M. Garzia13, L. Fiori14, A. Rago15, P. Arcuri4, E. Rossi4, M. Capriata5, M. Offidani3, A. Andriani2, R. Latagliata2

1 UOC Hematology, San Giovanni-Addolorata Hospital, Rome, Italy
2 UOC Hematology - ASL Viterbo – Santa Rosa Hospital, Italy
3 Hematology Clinic, AOU delle Marche, Ancona, Italy
4 Hematology Clinic, Policlinico Agostino Gemelli, Rome, Italy
5 Azienda Ospedaliera Universitaria Policlinico Umberto I, Rome, Italy
6 Hematology Unit, Pescara Hospital, Italy
7 Hematology, Sant’Andrea Hospital, Rome, Italy
8 UOSD Ematologia Civitanova Marche AST, Macerata, Italy
9 UOC di Ematologia, Trapianto di Cellule Staminali e Terapia Genica, Frosinone, Italy
10 UOC Hematology, Sant’Eugenio Hospital, Rome, Italy
11 Hematolgy Unit IRCCS Regina Elena National Cancer Institute, Rome, Italy
12 UOC Hematology Campus Biomedico, Rome, Italy
13 UOC Hematology and stem cell transplant, San Camillo Hospital, Rome, Italy
14 UOC Hematology Santa Maria Goretti,Hospital, Latina, Italy
15 UOSD Ematologia ASL Roma1, Rome, Italy
Multiple Myeloma Elderly Inflammation Score
https://doi.org/10.3324/haematol.2026.s2.14060

P21 | THE LONG TERM PROGNOSTIC IMPACT OF CHROMOSOME 1 ABNORMALITIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS (94 Online Views)

N. Iannozzi1, G. Sammarelli2, G. Todaro2, A. Poletti1, M. Scita2, B. D. Palma2, M. Bernardi2, C. Sitzia1, N. Giuliani1|2|3

1 University of Parma, Italy
2 Hematology Unit-University Hospital of Parma, Italy
3 Multiple myeloma and monoclonal gammopathies program, University Hospital of Parma, Italy
Multiple Myeloma Chromosome 1 abnormalities NDMM
https://doi.org/10.3324/haematol.2026.s2.14075

P22 | WHEN TRIAL DESIGN MEETS APPROVED MAINTENANCE: A SINGLE-CENTER REAL-WORLD EXPERIENCE WITH DARA-VTD INDUCTION AND CONSOLIDATION FOLLOWED BY LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (100 Online Views)

A. Belotti1, S. Terlizzi2, S. Martorana2, R. Ribolla1, C. Crippa1, S. Ferrari1, N. Bianchetti1, C. Bottelli1, C. Cattaneo1, M. Chiarini3, V. Giustini3, A. Roccaro4, A. Tucci1

1 Department of Hematology, ASST Spedali Civili di Brescia, Italy
2 University of Brescia, Italy
3 Clinical Chemistry Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Italy
4 Clinical Research Development and Phase I Unit, ASST Spedali Civili di Brescia, Italy
CASSIOPEIA trial Dara-VTd Transplant-eligible
https://doi.org/10.3324/haematol.2026.s2.14046

P23 | DARA-VTD AND ASCT+ LENALIDOMIDE LED TO HIGH COMPLETE REIMISSION AND MINIMAL RESIDUAL DISEASE NEGATIVITY RATES BY NGF: A REAL-WORLD STUDY OF THE TUSCAN MYELOMA NETWORK IN 228 PATIENTS (99 Online Views)

V. Venanzi1, S. Ciofini1, E. Antonioli2, G. Buda3, E. Bestoso1, D. Raspadori1, V. Candi4, L. Pengue2, M.L. Del Giudice3, A. Caremani4, S. Moretti5, G. Fontanelli5, I. Attucci2, M. T. Pirrotta5, C. Biagiotti5, S. Birtolo5, S. Grammatico5, S. Pilerci6, L. Notarfranchi7, G. Tancredi3, S. Galimberti3, M. Bocchia1, A. Gozzetti1

1 Department of Medicine Surgery and Neuroscience, Hematology, University of Siena, Italy
2 Department of Hematology, Careggi Hospital and University of Florence, Italy
3 Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Italy
4 Hematology Unit,Ospedale S. Donato, Arezzo, Italy
5 USL Toscana Centro, SOC Oncoematologia, Italy
6 Hematology Ospedale della Versilia, Lucca, Italy
7 Hematology Massa Carrara, Italy
CASSIOPEIA Trial Multiple Myeloma Tuscan network DARA-VTD
https://doi.org/10.3324/haematol.2026.s2.14065

P24 | APPROACHING CURE IN MULTIPLE MYELOMA: A DUAL-CENTER EXPERIENCE AMONG PATIENTS DIAGNOSED BEFORE 2010 (90 Online Views)

G. Cengiz Seval1, H. Aytekin2, T. Otlu1, U. Calıs1, M. Beksac1|2

1 Ankara University Faculty of Medicine Department of Hematology, Turkey
2 Istinye University Ankara Liv Hospital, Turkey
Multiple myeloma NDMM Minimal Residual Disease
https://doi.org/10.3324/haematol.2026.s2.14110

P25 | REAL-WORLD OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA: EVIDENCE SUPPORTING BORTEZOMIB–LENALIDOMIDE–DEXAMETHASONE AS A PREFERRED REGIMEN WITHOUT ANTI-CD38 ANTIBODIES (79 Online Views)

A. Jungova1, M. Stork2, I. Spicka3, J. Radocha4, J. Minarik5, P. Pavlicek6, J. Mihalyova7, L. Pour2, J. Straub3, V. Maisnar4, T. Pika5, T. Dekojova1, J. Soukup6, T. Popkova7, K. Mensikova2, F. Sedlák3, J. Pospiskova4, I. Boichuk2, P. Krhovska5, T. Stopka3, P. Jindra1, T. Jelínek7, Z. Knechtová2, V. Capounova4, V. Latal5, L. Muronova7, A. Heindorfer8, J. Ullrychova9, M. Sykora10, P. Kessler11, R. Hajek7|12

1 Charles University Hospital, Pilsen, Czech Republic
2 University Hospital, Brno, Czech Republic
3 First Faculty of Medicine Charles University, Prague, Czech Republic
4 Charles University Hospital, Hradec Kralove, Czech Republic
5 University Hospital, Olomouc, Czech Republic
6 3rd Faculty of Medicine Charles University Kralovske Vinohrady, Prague, Czech Republic
7 University Hospital, Ostrava, Czech Republic
8 Liberec Regional Hospital, Czech Republic
9 Masaryk Hospital in Usti nad Labem, Czech Republic
10 Hospital Ceske Budejovice, Czech Republic
11 Hospital Pelhrimov, Czech Republic
12 Faculty of Medicine University of Ostrava, Czech Republic
NDMM Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14036

P26 | CORRELATION OF THE CIRCULATING TUMOR CELLS AND R2-ISS SCORE IN NEWLY DIAGNOSED MYELOMA PATIENTS: RWE EXPERIENCE (79 Online Views)

N. Kecman1, M. Mitrovic1, A. Sretenovic1|2, Z. Bukumiric2|3, I. Tanovic1, N. Kraguljac Kurtovic1, J. Jovanovic1, J. Bila1|2

1 Clinic of Hematology University Clinical Center of Serbia, Belgrade, Serbia
2 Medical Faculty, University of Belgrade, Serbia
3 Institute of Biostatistics, Medical Faculty, University of Belgrade, Serbia
Multiple Myeloma Circulating tumor cells R2-ISS score
https://doi.org/10.3324/haematol.2026.s2.14113

P27 | OPTIMIZATION OF MELPHALAN DOSAGE THROUGH ELIMINATION OF METABOLITES VIA HEMODIALYSIS IN MULTIPLE MYELOMA PATIENTS WITH RENAL IMPAIRMENT (94 Online Views)

C. Schaaf1, J. Steinhaus1, M. Högner2, M. Verbeek2, D. Czock3, K. Kleigrewe4|5, F. Hackbarth4|5, M. Braunisch1, R. Günthner1, J. Jung2, S. Niedermayer1, S. Röder1, T. Langseder1, J. Matschkal1, J. Lecce1, L. Platen1, N. Hannane1, L. Mertens2, J. Carbajo-Lozoya1, C. Fiorentini6, S. Glowka6, F. Keller7, U. Heemann1, C. Schmaderer1, F. Bassermann2, L. Renders1, C. Küchle1

1 Technical University of Munich, TUM School of Medicine and Health, Department of Nephrology, TUM University Hospital, Germany
2 Technical University of Munich, TUM School of Medicine and Health, Department of Medicine III, Hematology and Oncology, TUM University Hospital, Germany
3 University of Heidelberg, University Hospital Heidelberg, Internal Medicine IX, Department of Clinical Pharmacology and Pharmacoepidemiology, Germany
4 Technical University of Munich, Bavarian Center for Biomolecular Mass Spectrometry
5 (BayBioMS), Technology Core Facilities, Germany
6 Technical University of Munich, TUM School of Medicine and Health, Preventive and Sports Medicine Centre for Sports Cardiology, TUM University Hospital, Germany
7 University of Ulm, Ulm University Hospital, Faculty of Medicine, Institute for Experimental and Clinical Pharmacology, Toxicology and Natural Medicine, Germany
Multiple Myeloma Renal Impairment Melphalan
https://doi.org/10.3324/haematol.2026.s2.14076

P28 | ON DEMAND PLERIXAFOR FOR STEM CELL MOBILIZATION WITH G-CSF ONLY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMAB: A SINGLE CENTER EXPERIENCE (97 Online Views)

B. Skopec1|2, L. Cemazar1, M. Skerget1|2

1 University Medical Center Ljubljana, Slovenia
2 University of Ljubljana, Faculty of Medicine, Slovenia
NDMM Plerixafor HSC Mobilization
https://doi.org/10.3324/haematol.2026.s2.14101

P29 | PLATELET AGGREGATION AND THROMBIN GENERATION IN MULTIPLE MYELOMA: A PROSPECTIVE STUDY (89 Online Views)

M. Biglietto1, R. Mormile1, A. Piciocchi1, F. Fazio1, M. Capriata1, S. Sorella1, B. Mandelli1, D. Kasmi1, E. Baldacci1, A. Chistolini1, M.T. Petrucci1, C. Santoro1

1 Department of Translational and Precision Medicine, Sapienza University of Rome, Italy
Multiple Myeloma Platelet Functions NDMM
https://doi.org/10.3324/haematol.2026.s2.14039

P30 | PROGNOSTIC IMPACT OF THE LYMPHOCYTE-TO-ALBUMIN RATIO IN PATIENTS WITH MULTIPLE MYELOMA (92 Online Views)

G.A. Cagliyan

Pamukkale University Department of Hematology, Denizli, Turkey
Lymphocyte-to-albumin ratio Prognostic biomarkers Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14057

P31 | PROGNOSTIC IMPACT OF INTERPHASE FISH IN MULTIPLE MYELOMA: SINGLE-CENTER IRISH EXPERIENCE (82 Online Views)

T. Pramod1, A. Bannaga1, S. Kumar1, B. Hennessy1, E. E. Hassadi1

1 University Hospital Waterford, Ireland
Multiple Myeloma Prognostic factors FISH abnormalities
https://doi.org/10.3324/haematol.2026.s2.14095

P32 | MULTIPLE MYELOMA PRESENTING AS ACUTE BACK PAIN AND KIDNEY INJURY: A DIAGNOSTIC CHALLENGE (69 Online Views)

M. Hammad1, O. Elsegai2

1 Royal Preston Hospital, Preston, UK
2 Salmaniya Medical Complex, Manama, Bahrain
Multiple Myeloma Musculoskeletal symptoms Renal Impairment
https://doi.org/10.3324/haematol.2026.s2.14106
EMN 2026 - Session 3. Relapsed/refractory multiple myeloma

P33 | ARLOCABTAGENE AUTOLEUCEL, A GPRC5D-TARGETED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1 SAFETY AND EFFICACY RESULTS IN PATIENTS WITH 1–3 PRIOR REGIMENS (101 Online Views)

S. Bal1, M. Htut2, J. Berdeja3, L. Anderson4, A. Rossi5, T. Gregory6, L. Costa1, H. Hu7, Z. Guo7, J. Chen7, K. Jordahl7, N. Sarkis7, S. Ziyad7, W.M. Kao7, A. Kaeding7, M. Burgess7, O. Nadeem8

1 University of Alabama at Birmingham, USA
2 City of Hope Comprehensive Cancer Center, Duarte, USA
3 Greco-Hainsworth Tennessee Oncology Center for Research, Nashville, USA
4 Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, USA
5 Icahn School of Medicine at Mount Sinai, New York, USA
6 Colorado Blood Cancer Institute, Sarah Cannon Cancer Network, Denver, USA
7 Bristol Myers Squibb, Princeton, USA
8 Dana-Farber Cancer Institute, Boston, USA
RRMM CAR-T cells BCMA
https://doi.org/10.3324/haematol.2026.s2.14112

P34 | CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: BIOMARKER ANALYSES FROM CAMMA 1 ARM B (77 Online Views)

R. Popat1, S. Harrison2, C. H. Riley3, H.S. Mian4, A. Spencer5, N. Lavi6, L. Paris7, T. Jelínek8, M. Szarejko9, S. Grosicki10, K. Kim11, I. Sandhu12, S. Chebon13, T. Tyagi14, P. Sewpaul15, L. Richardson15, K. Trunzer13, A. Mishra14, S. Trudel16

1 University College London Hospitals NHS Foundation Trust, UK
2 Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University and The Royal Melbourne Hospital, Australia
3 Rigshospitalet, Copenhagen, Denmark
4 McMaster University, Hamilton, Canada
5 Alfred Health-Monash University, Melbourne, Australia
6 Rambam Health Care Campus, Haifa, Israel
7 ASST Papa Giovanni XXIII, Bergamo, Italy
8 Department of Hematooncology, University Hospital Ostrava and University of Ostrava, Czech Republic
9 Medical University of Gdansk, Poland
10 Medical University of Silesia, Katowice, Poland
11 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
12 Cross Cancer Institute, University of Alberta, Edmonton, Canada
13 F. Hoffmann-La Roche Ltd, Basel, Switzerland
14 Genentech, Inc, South San Francisco, USA
15 Roche Products Ltd, Welwyn, UK
16 Princess Margaret Cancer Centre and University of Toronto, Canada
CAMMA 1 study BCMA Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14083

P35 | PROLONGED ELRANATAMAB TREATMENT INTERRUPTION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MagnetisMM-3 RETROSPECTIVE ANALYSIS (82 Online Views)

E. Searle1|2, A. Lesokhin3, R. Niesvizky4, B. Arnulf5, S. Larson6, C.. Strouse7, C. Fernandez De Larrea8, D. Vesole9, Y. Nagai10, S.T. Sullivan11, E. Leip11, N. Bahlis12

1 The Christie NHS Foundation Trust, Manchester, UK
2 University of Manchester, UK
3 Memorial Sloan Kettering Cancer Center, New York, USA
4 Weill Cornell Medicine/New York Presbyterian Hospital, USA
5 Hôpital Saint-Louis, APHP, Université Paris, France
6 UCLA Medical Center, Santa Monica, USA
7 Carver College of Medicine,Iowa City, USA
8 Hospital Clínic, Barcelona, Spain
9 John Theurer Cancer Center, Hackensack, USA
10 Kobe City Medical Center General Hospital, Japan
11 Pfizer Inc, Cambridge, USA
12 Arnie Charbonneau Cancer Institute, Calgary, Canada
RRMM BCMA MagnetisMM-3
https://doi.org/10.3324/haematol.2026.s2.14090

P36 | EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER CILTACABTAGENE AUTOLEUCEL: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (78 Online Views)

E. Zamagni1, B. Dhakal2, S. Iida3, M.H. Sidiqi4|5, S.S. Yoon6, N. Callander7, C. Touzeau8|9|10|11, Q. Li12, A. Balogh12, A. Slaughter12, N. Benachour12, C. Lonardi12, A. Ghosh12, M. Vogel12, N. Lendvai12, T. Lengil12, M. Koneru13, N. Patel13, O. Costa Filho13, V. Mahajan13, J. Martínez-López14, K. Yong15, K. Weisel16, X. Leleu17

1 University of Bologna, Italy
2 Medical College of Wisconsin, Milwaukee, USA
3 Nagoya City University, Japan
4 Fiona Stanley Hospital, Perth, Australia
5 Curtin University, Perth, Australia
6 Seoul National University, Korea
7 University of Wisconsin, Madison, USA
8 Centre Hospitalier Universitaire Hotel Dieu, Nantes, France
9 Université d’Angers, Nantes, France
10 Université de Nantes, France
11 French Ministry of Health, Nantes, France
12 Johnson & Johnson
13 Legend Biotech USA Inc, Somerset, USA
14 Complutense University, Madrid, Spain
15 University College London, UK
16 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
17 CHU Poitiers, France
Multiple Myeloma CARTITUDE-4
https://doi.org/10.3324/haematol.2026.s2.14045

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (89 Online Views)

R. Popat1, K.M. Kortüm2, H. Magen3, V. Mykytiv4, C. Liberatore5, E. Zamagni6, M.C. Da Vià7, E. Antonioli8, M. Hansson9, D. Santra10, D. Greer10, K. Subrt11, P. Hu11, E. Aeby11, N. Francella11, N.M. Suñe11, A. Perrot12, K. Uttervall13

1 University College London Hospitals NHS Foundation Trust, UK
2 University Hospital of Würzburg, Germany
3 Tel Aviv University, Israel
4 Cork University Hospital, Ireland
5 Ospedale Santo Spirito, Pescara, Italy
6 University of Bologna, Italy
7 IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
8 Careggi Hospital and University of Florence, Italy
9 Sahlgrenska University Hospital, Gothenburg, Sweden
10 Parexel International
11 Johnson & Johnson
12 Université de Toulouse, France
13 Karolinska University Hospital, Stockholm, Sweden
Multiple Myeloma REALiTAL Trial RRMM
https://doi.org/10.3324/haematol.2026.s2.14051

P38 | SAFETY AND EFFICACY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM PHASE 1b OF RedirecTT-1: RESULTS WITH AN EXTENDED MEDIAN FOLLOW-UP OF 3 YEARS (74 Online Views)

E.M. Ocio1|2, M-V. Mateos3, H. Magen4, M. Gatt5, M. Sebag6, K. Kim7, C-K. Min8, S-S. Yoon9, M.P. Chu10, P. Rodríguez-Otero11, I. Avivi4, N.A. Quijano Cardé12, M. Krevvata12, T. Henninger12, P. Thakkar12, M. Festa12, L. Huang12, J.X. Zhou12, M. Takamoto12, L. Pei12, J. Lu12, C. Maffucci12, E. Scott12, A. Oriol13, D. Morillo14, Y.C. Cohen4

1 Hospital Universitario Marqués de Valdecilla, Santander, Spain
2 Universidad de Cantabria, Santander, Spain
3 University Hospital of Salamanca, Spain
4 Tel Aviv University, Israel
5 Hebrew University of Jerusalem, Israel
6 McGill University, Montreal, Canada
7 Sungkyunkwan University School of Medicine, Seoul, Korea
8 The Catholic University of Korea, Seoul, Korea
9 Seoul National University College of Medicine, Korea
10 Alberta Health Services, Edmonton, Canada
11 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
12 Johnson & Johnson
13 Hospital Germans Trias i Pujol, Badalona, Spain
14 University Hospital Fundación Jiménez Díaz, Madrid, Spain
RRMM RedirecTT-1 Follow-up
https://doi.org/10.3324/haematol.2026.s2.14054

P39 | RANDOMIZED PHASE II DOSE OPTIMIZATION STUDY OF INOBRODIB (CCS1477) IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (59 Online Views)

E. Searle1, V. Campbell2, C. Pawlyn3, D. Vogl4, S. Holstein5, S. Gooding6, M. Jenner7, T. Creasey8, A. Chaidos9, P. Rodríguez-Otero10, F. Al-Kaisi11, A. Brearton12, S. Moore6, J. O’Nions13, T. Somervaille1, T. Knurowski14, K. Clegg14, S. Paul14, K. Frese14, N. Joseph15

1 The Christie NHS Foundation Trust, Manchester, UK
2 Western General Hospital, Edinburgh, UK
3 The Royal Marsden NHS Foundation Trust, London, UK
4 Hospital of the University of Pennsylvania, Philadelphia, USA
5 University of Nebraska Medical Center, Omaha, USA
6 Oxford University Hospitals NHS Foundation Trust, Oxford, UK
7 University Hospital Southampton NHS Foundation Trust, UK
8 Northern Centre for Cancer Care, Newcastle upon Tyne, UK
9 Imperial College Healthcare NHS Trust, London, UK
10 Clínica Universidad de Navarra, Pamplona, Spain
11 Royal Derby Hospital, UK
12 The Clatterbridge Cancer Centre, Liverpool, UK
13 University College London Hospital, UK
14 CellCentric Ltd, Cambridge, UK
15 Emory Winship Cancer Institute, Atlanta, USA
Multiple Myeloma Inobrodib RRMM
https://doi.org/10.3324/haematol.2026.s2.14069

P40 | EFFICACY AND SAFETY OF TALQUETAMAB + TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE: UPDATED PHASE 2 RESULTS FROM THE RedirecTT-1 STUDY WITH EXTENDED FOLLOW-UP (90 Online Views)

M.V. Mateos1, P. Rodríguez-Otero2, S.Z. Usmani3, S. Kumar4, J.C. Ye5, S. Atrash6, H. Magen7, H. Quach8, M.P. Chu9, S. Trudel10, J. Richter11, H. Chuah12, M. Gatt13, E. Medvedova14, S. Raza15, D.H. Yoon16, T. Ishida17, J.V. Matous18, L. Rosiñol19, K. Onodera20, C. Maffucci21, E. Scott21, C. Heuck21, J. Zhang21, T. Henninger21, L. O’Rourke21, P. Thakkar21, M. Festa21, L. Huang21, J. Zhou21, M. Takamoto21, L. Pei21, J. Lu21, N. Au21, M. Krevvata21, Y.C. Cohen7

1 University Hospital of Salamanca, Spain
2 Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
3 Memorial Sloan Kettering Cancer Center, New York, USA
4 Mayo Clinic Rochester, USA
5 University of Texas, Houston, USA
6 Levine Cancer Institute-Atrium Health, Charlotte, USA
7 Tel Aviv University, Israel
8 University of Melbourne, Australia
9 Alberta Health Services, Edmonton, Canada
10 Princess Margaret Cancer Centre, Toronto, Canada
11 Mount Sinai Medical Center, New York, USA
12 Royal Perth Hospital, Australia
13 Hebrew University of Jerusalem, Israel
14 Oregon Health and Science University, Portland, USA
15 Cleveland Clinic, USA
16 University of Ulsan College of Medicine, Seoul, Korea
17 Japanese Red Cross Medical Center, Tokyo, Japan
18 Colorado Blood Cancer Institute, Denver, USA
19 Hospital Clínic de Barcelona, Spain
20 Tohoku University Hospital, Sendai, Japan
21 Johnson & Johnson
Multiple Myeloma RedirecTT-1 trial RRMM
https://doi.org/10.3324/haematol.2026.s2.14055

P41 | FIRST RESULTS OF REALiTEC-2: SECOND COHORT OF REALiTEC, AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ROUTINE CLINICAL PRACTICE (66 Online Views)

R. Popat1, K. Uttervall2, K.M. Kortüm3, H. Magen4, M. Hansson5, T. Shragai6, E. Terpos7, C. T. Hansen8, S. Manier9|10, H. Gregersen11, Ø.M. Ottestad12, C. Touzeau13, E. Hatjiharissi14|15, S.L. Farmer16, E. Katodritou17, E. Spanoudakis18, M.Ø. Vase19, C. Liberatore20|21, M. Papathanasiou22, M.K. Angelopoulou7|23, E. Clavero24, R. Kittus25, P. Smirnov25, P. Hu25, D. Santra26, C. Albrecht25, E. Rubio-Azpeitia25, A. Perrot27

1 University College London Hospitals NHS Foundation Trust, UK
2 Karolinska University Hospital, Stockholm, Sweden
3 University Hospital of Würzburg, Germany
4 Tel-Aviv University, Israel
5 Sahlgrenska University Hospital, Gothenburg, Sweden
6 Tel-Aviv Sourasky Medical Center, Israel
7 National and Kapodistrian University of Athens, Greece
8 Odense University Hospital, Denmark
9 University of Lille, France
10 Centre Hospitalier Universitaire Lille, France
11 Aalborg University Hospital, Denmark
12 Akershus University Hospital, Lørenskog, Norway
13 University Hospital Hôtel-Dieu, Nantes, France
14 AHEPA University Hospital, Thessaloniki, Greece
15 Aristotle University of Thessaloniki, Greece
16 Vejle Hospital, Denmark
17 Theagenio Cancer Hospital, Thessaloniki, Greece
18 Democritus University of Thrace, Alexandroupolis, Greece
19 Aarhus University Hospital, Denmark
20 Santo Spirito Hospital, Pescara, Italy
21 "G d'Annunzio" University, Chieti, Italy
22 G Papanicolaou Hospital, Thessaloniki, Greece
23 Laiko General Hospital, Athens, Greece
24 Hospital Universitario Virgen De Las Nieves, Granada, Spain
25 Johnson and Johnson
26 Parexel International on behalf of Johnson & Johnson, Sheffield, UK
27 Université de Toulouse, France
REALiTEC-2 Trial RRMM Teclistamab
https://doi.org/10.3324/haematol.2026.s2.14038

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (71 Online Views)

A. Perrot1, M. Kortüm2, R. Popat3, K. Uttervall4, M.V. Mateos5, K. Weisel6, K. Van Nimwegen7, J. Diels7, F. Ong7, R. Morano7, E. Rubio-Azpeitia7, P. Moreau8

1 Universite de Toulouse, France
2 University Hospital of Würzburg, Germany
3 University College London Hospitals NHS Foundation Trust, UK
4 Karolinska University Hospital, Stockholm, Sweden
5 Hospital Universitario de Salamanca, Spain
6 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 Johnson & Johnson
8 University Hospital Hôtel-Dieu, Nantes, France
Multiple Myeloma RRMM Teclistamab
https://doi.org/10.3324/haematol.2026.s2.14041

P43 | SELINEXOR, MEZIGDOMIDE, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RELAPSED OR ARE INELIGIBLE FOR T-CELL–REDIRECTING THERAPY: STOMP PHASE 1 PRELIMINARY RESULTS (68 Online Views)

C. Mo1, C. Gasparetto2, C. Costa2, A.J. Cowan3, T. Mark4, Y. Chai4, T. Kashyap4, J. Katz5, M. Amatangelo5, P.G. Richardson1

1 Dana-Farber Cancer Institute, Boston, USA
2 Duke Cancer Institute, Durham, USA
3 University of Washington, Seattle, USA
4 Karyopharm Therapeutics, Newton, USA
5 Bristol Myers Squibb, Princeton, USA
Multiple Myeloma RRMM STOMP trial
https://doi.org/10.3324/haematol.2026.s2.14043

P44 | EARLIER USE OF CILTACABTAGENE AUTOLEUCEL IS ASSOCIATED WITH BETTER IMMUNE FITNESS AND STRONGER IMMUNE EFFECTS AS SHOWN BY CORRELATIVE ANALYSIS OF PERIPHERAL BLOOD AND THE BONE MARROW TUMOR MICROENVIRONMENT FROM THE CARTITUDE-4 STUDY (80 Online Views)

N.W.C.J. Van De Donk1, S. Parekh2, K. Li3, Y. Lin4, T.G. Martin5, S. Han2, R. Montes De Oca2, M. Suraneni3, M. Gormley2, B. Hodkinson2, J. Yuan2, F. Wang3, A. Kumar2, D. Yin2, D. Smirnov2, J. Patel2, N. Lendvai3, D. Madduri3, J. Zhu6, M. Koneru6, N. Patel6, D. Geng6, V. Plaks2, S. Harrison7|8|9

1 Vrije Universiteit Amsterdam, The Netherlands
2 Icahn School of Medicine at Mount Sinai, New York, USA
3 Johnson & Johnson
4 Mayo Clinic, Rochester, USA
5 University of California San Francisco, USA
6 Legend Biotech USA Inc, Somerset, USA
7 Peter MacCallum Cancer Centre, Melbourne, Australia
8 Royal Melbourne Hospital, Australia
9 University of Melbourne, Parkville, Australia
CARTITUDE-4 Prognostic Biomarkers RRMM
https://doi.org/10.3324/haematol.2026.s2.14058

P45 | MODELING DORMANCY IN MULTIPLE MYELOMA: FUNCTIONAL AND TRANSCRIPTOMIC CHARACTERIZATION OF SERUM STARVATION AND CHEMOTHERAPY-INDUCED STATES (69 Online Views)

Z.S. Najafabadi1, N. Afrin2, M. Helal2, H. Fischer1, M. John2, E. Stanojkovska1, J. Mersi1, S. Kadel1, J. Waldschmidt1, M. Kortüm1, K. Kretzschmar2, H. Einsele1, A. Riedel2, L. Rasche1|2

1 Internal Medicine II, Universitätsklinikum Würzburg, Germany
2 Mildred Scheel Early Career Centre for Cancer Research Würzburg, The Julius-Maximilians-Universität Würzburg, Germany
Multiple Myeloma Cancer cell dormancy 3D Model
https://doi.org/10.3324/haematol.2026.s2.14066

P46 | CIRCULATING PLASMA CELLS AS A DYNAMIC BIOMARKER IN MULTIPLE MYELOMA PATIENTS RECEIVING CAR-T AND BISPECIFIC ANTIBODY THERAPY (74 Online Views)

I. Vigliotta1, A. Varacalli1, M. Talarico1|2, M. Puppi1|2, S. Armuzzi2, B. Taurisano2, I. Pistis1, V. Solli2, V. M. Vuong2, E. Borsi1, A. Vitale1, G. Mazzocchetti3|4, A. Croce2, M. Martello1, A. Poletti2, M. Cavo2, E. Manzato1|2, E. Zamagni1|2, C. Terragna1

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
2 Department of Medical and Surgical Sciences - University of Bologna, Italy
3 FABIT-Department of Pharmacy and Biotechnology, University of Bologna, Italy
4 Computational and Chemical Biology, Italian Institute of Technology, CMP3VdA, Aosta, Italy
RRMM CAR-T Circulating plasma cells
https://doi.org/10.3324/haematol.2026.s2.14092

P47 | UTILITY AND SENSITIVITY OF WETT-SA53 TO MEASURE DYSGEUSIA ASSOCIATED WITH TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY DATA FROM THE TALISMAN STUDY (86 Online Views)

R. Popat1, N.W.C.J. Van De Donk2|3, B. Faiman4, J. Yuda5, K. Kim6, A. Costa7, A. Laheij2|3, R.L. Doty8, J. Omel9, B. Lipe10, L. Sanchez11, A. Chari12, A. Lin13, H. Sroussi14, M. Fernandez15, K.S. Gray15, G. Aguilar15, K. Bolyard15, J. Schultz15, K. Qi15, D. Cortes-Selva15, J. Zhang15, C. Heuck15, K. Hawks15, K. Tian15, M. França15, L. Rasche16

1 University College London Hospitals NHS Foundation Trust, UK
2 Amsterdam University Medical Center, The Netherlands
3 Vrije Universiteit Amsterdam, The Netherlands
4 Cleveland Clinic, USA
5 National Cancer Center Hospital East, Kashiwa, Japan
6 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
7 D’or Institute for Research and Education, São Paulo, Brazil
8 University of Pennsylvania Smell and Taste Center, Philadelphia, USA
9 The Central Nebraska Myeloma Support Group, Grand Island, USA
10 University of Rochester Medical Center, USA
11 Icahn School of Medicine at Mount Sinai, New York, USA
12 University of California, San Francisco, USA
13 University of Pennsylvania, Philadelphia, USA
14 Brigham and Women’s Hospital, and Harvard School of Dental Medicine, Boston, USA
15 Johnson & Johnson
16 University Hospital of Würzburg, Germany
TALISMAN study Multiple Myeloma RRMM
https://doi.org/10.3324/haematol.2026.s2.14053

P48 | LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA (71 Online Views)

D. Dytfeld1, L.J. Costa2, A. Oriol3, S. Manier4|5, P.M. Voorhees6, Y. Lin7, M. Htut8, W. Roeloffzen9, P. J. Ho10|11, U. Shah12|13, M. Zhao14, Q. Li15, A. Balogh15, K. Li15, A. Slaughter15, N. Benachour15, C. Lonardi15, A. Ghosh15, H. Sun15, N. Lendvai15, T. Lengil15, N. Patel16, M. Koneru16, E. Florendo16, O. C. Filho16, V. Mahajan16, P. Rodríguez-Otero17, C. Strouse18, A.K. Stewart19|20, S. Sidana21

1 Poznan University of Medical Sciences, Poznań, Poland
2 University of Alabama at Birmingham, USA
3 Hospital Germans Trias i Pujol, Barcelona, Spain
4 University of Lille, France
5 Centre Hospitalier Universitaire Lille, France
6 Wake Forest University, Charlotte, USA
7 Mayo Clinic, Rochester, USA
8 City of Hope Comprehensive Cancer Center, Duarte, USA
9 University Medical Center Groningen, The Netherlands
10 Royal Prince Alfred Hospital, Sydney, Australia
11 The University of Sydney, Australia
12 Memorial Sloan Kettering Cancer Center, New York, USA
13 Weill Cornell Medical College, New York, USA
14 IQVIA, Shangai, China
15 Johnson & Johnson
16 Legend Biotech USA Inc, Somerset, USA
17 Universidad de Navarra, Pamplona, Spain
18 University of Iowa, Iowa City, USA
19 University Health Network, Toronto, Canada
20 The Princess Margaret Cancer Centre, Toronto, Canada
21 Stanford University, USA
CARTITUDE-4 Multiple Myeloma Progression free
https://doi.org/10.3324/haematol.2026.s2.14061

P50 | INPATIENT VS. OUTPATIENT TREATMENT MANAGEMENT WITH TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A COST AND HEALTHCARE RESOURCE UTILIZATION ANALYSIS (73 Online Views)

N.W.C.J. Van De Donk1, R. Wester2, I. Nijhof3, C. Albrecht4, R. Morano5, C. Entrala6, K. Van Nimwegen1|2|3|4|5|6

1 Amsterdam University Medical Center, The Netherlands
2 Erasmus Medical Center, Rotterdam, The Netherlands
3 St. Antonius Ziekenhuis, Nieuwegein, The Netherlands
4 Johnson & Johnson, Paris, France
5 Johnson & Johnson, Madrid, Spain
6 Johnson & Johnson, Breda, The Netherlands
Multiple Myeloma RRMM Treatment Management
https://doi.org/10.3324/haematol.2026.s2.14040

P51 | EVOLVING ATTRITION RATES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE OVER A 30-YEARS PERIOD FROM A SINGLE CENTER EXPERIENCE (50 Online Views)

G. Giunta1, C. Bellofiore2, E. Scalisi1, F. Elia2|1, B. Garibaldi2, C. Finocchiaro1, F. Di Raimondo2|1, A. Romano2|1, C. Conticello2

1 Postgraduate School of Hematology, University of Catania, Italy
2 Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy
https://doi.org/10.3324/haematol.2026.s2.14086

P52 | CILTACABTAGENE AUTOLEUCEL OUT-OF-SPECIFICATION MANUFACTURING OUTCOMES IMPROVE WITH EARLIER LINES OF THERAPY (60 Online Views)

R. Bowden1, H. Van Eeckhoutte1, G. Chow1, G. Choudhary1, L. Kallenbach1, V. Alegria1, M. Perciavalle2, J. Salmon2, J. Kang2, M. Mondon2, J. Vanak1, D. Ciccone1, P. Millili1, M. Onorata1, V. Plaks1, M. Merz3

1 Johnson & Johnson, USA
2 Legend Biotech USA Inc, Somerset, USA
3 Memorial Sloan Kettering Cancer Center, New York, USA
Ciltacabtagene autoleucel Multple Myeloma Manufacturing data
https://doi.org/10.3324/haematol.2026.s2.14059

P53 | NATIONWIDE EXPERIENCE WITH STANDARD OF CARE IDECABTAGENE VICLEUCEL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL WORLD STUDY ON BEHALF OF THE GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO FOUNDATION (56 Online Views)

M. Puppi1|2|3, M. Pennisi4, F. Monaco5, L. Paris6, S. Aquino7, F. Ciceri8, M.C. Goldaniga9, M. Musso10, G. Buda11, M. Martino12, P. Chiusolo13, F. Fazio14, R. Mina15, F. Patriarca16, M.C. Tisi17, P. Tacchetti1, V. Marasco4, F. Ardizzoia1|2|3, M. Talarico1|2|3, K. Mancuso1|2|3, E. Maffini1, C. Carniti4, C. Terragna1, E. Zamagni1|2|3, F. Bonifazi1, M. Cavo2|3, P. Corradini4

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Italy
2 Department of Medical and Surgical Sciences
3 (DIMEC), University of Bologna, Italy
4 Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, University of Milan, Italy
5 AOSS Antonio e Biagio e Cesare Arrigo-SC Ematologia, Alessandria, Italy
6 ASST Papa Giovanni XXIII, Bergamo – SC Ematologia, Italy
7 Ematologia e Terapie cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy
8 Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy
9 Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
10 Dipartimento Oncologico "La Maddalena", UOC di Oncoematologia e TMO, Palermo, Italy
11 Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa, Italy
12 Stem Cell Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy
13 Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
14 Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of Rome, Italy
15 AOU Città della Salute e della Scienza di Torino and the Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy
16 Clinica Ematologica ed Unità di Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
17 Hematology Unit, San Bortolo Hospital, Vicenza, Italy
RRMM GIMEMA CAR-T
https://doi.org/10.3324/haematol.2026.s2.14078

P54 | EVOLVING OUTCOMES IN MULTIPLE MYELOMA REAL-WORLD PRACTICE: 30-YEARS SINGLE CENTER EXPERIENCE (56 Online Views)

G. Giunta1, C. Bellofiore2, E. Scalisi1, V. Del Fabro3, F. Elia1|2, B. Garibaldi2, C. Finocchiaro1, F. Di Raimondo1|2, A. Romano1|2, C. Conticello2

1 Postgraduate School of Hematology, University of Catania, Italy
2 Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy
3 Faculty of Medicine and Surgery, “Kore” University of Enna, Italy
Multiple myeloma Real-World Practice Sicily
https://doi.org/10.3324/haematol.2026.s2.14085

P55 | MANAGEMENT OF NEUROLOGICAL TOXICITIES OF PATIENTS TREATED WITH IMMUNOTHERAPIES FOR MULTIPLE MYELOMA: A SINGLE-CENTER REAL WORLD EXPERIENCE (71 Online Views)

E. Manzato1|2, M. Puppi1|2, M. Talarico1|2, M. Iezza1|2, S. Masci1|2, S. Ghibellini1|2, A. Vitale2, S. Barbato1|2, P. Tacchetti1, L. Pantani1, K. Mancuso1|2, E. Zamagni1|2

1 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia L. A. Seràgnoli, Italy
2 Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Italy
Multiple Myeloma Neurological Toxicities RRMM
https://doi.org/10.3324/haematol.2026.s2.14068

P56 | BASELINE IMMUNE PROFILE PREDICTS RESPONSE TO BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD MONOCENTRIC EXPLORATORY ANALYSIS (65 Online Views)

R. Della Pepa1, A. Leone1, L. Esposito1, G.L. D'Elia1, V. Cerbone2, M. Raia2, G. Scalia2, F. Pane1

1 Division of Hematology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Italy
2 Clinical and Experimental Cytometry Unit, Centre for Advanced Biotechnology Franco Salvatore, CEINGE Biotecnologie Avanzate, Naples, Italy
https://doi.org/10.3324/haematol.2026.s2.14097

P57 | MELFLUFEN IS EFFECTIVE AND SAFE IN MULTIPLE MYELOMA PATIENTS WITH SEVERE RENAL IMPAIRMENT (73 Online Views)

C. Bellofiore1, V. Del Fabro2, C. Finocchiaro3, F. Elia1|3, D. Leotta3, B. Garibaldi1, A. Petronaci3, F. Di Raimondo1|3, A. Romano1|3, C. Conticello1

1 Division of Hematology, Azienda Policlinico-S. Marco, University of Catania, Italy
2 Faculty of Medicine and Surgery, “Kore” University of Enna, Italy
3 Postgraduate School of Hematology, University of Catania, Italy
RRMM Renal impairment Melflufen
https://doi.org/10.3324/haematol.2026.s2.14084

P58 | TRIAL IN PROGRESS: QUINTESSENTIAL-2 – A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VS. STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA EXPOSED TO LENALIDOMIDE (69 Online Views)

E. Lebel1, A. Abdulgawad2, S. Bramanti3, G. Garate4, P.J. Ho5, M. Keränen6, Y. Cohen7, M. Vase8, A. Khot9, I. Kristensen10, R. Leblanc11, C. Lee12, W. Legiec13, H. Magen14, M.V. Mateos15, D. Oh16, L. Pour17, N. Schutz18, A. Spyridonidis19, K. Weisel20, J. Zaucha21, S. Larson22, A. Varshavsky-Yanovsky23, K. Grazioli24, D. Basudhar24, H. Hu24, Y. Meng24, L. Eldjerou24, S. Bal25, S. Harrison9, R. Popat26, M. Raab27, P. Rodriguez-Otero28

1 Hadassah Medical Center, Jerusalem, Israel
2 Christie NHS Foundation Trust, Manchester, UK
3 IRCCS Istituto Clinico Humanitas, Rozzano, Italy
4 Hospital Aleman, Buenos Aires, Argentina
5 Royal Prince Alfred Hospital and University of Sydney, Camperdown, Australia
6 Helsinki University Hospital, Finland
7 Tel Aviv Sourasky Medical Center and Faculty of Medical and Health Sciences, Tel Aviv University, Israel
8 Aarhus Universitetshospital, Midtjylland, Denmark
9 Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia
10 Odense Universitetshospital, Denmark
11 Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Université de Montréal, Quebec, Canada
12 Royal Adelaide Hospital, Australia
13 St. John of Dukla Oncology Center of Lublin Land,Poland
14 Department of Hematology, Chaim Sheba Medical Center, Ramat-Gan, Faculty of Medicine, Tel Aviv University, Israel
15 Hospital Universitario de Salamanca, Spain
16 Monash Health and Monash University, Clayton, Victoria, Australia
17 Masaryk University and University Hospital Brno, Czech Republic
18 Hospital Italiano de Buenos Aires, Argentina
19 University Hospital of Patras, Greece
20 University Medical Center Hamburg-Eppendorf, Germany
21 Medical University of Gdańsk and University Clinical Center, Poland
22 UCLA Medical Center, Los Angeles, USA
23 Fox Chase Cancer Center Temple Health, Philadelphia, USA
24 Bristol Myers Squibb, Princeton, USA
25 University of Alabama at Birmingham, USA
26 University College London Hospital, UK
27 Universitaetsklinikum Heidelberg, Germany
28 Clinica Universidad de Navarra, Pamplona, Spain
QUINTESSENTIAL-2 Trial Multiple Myeloma RRMM
https://doi.org/10.3324/haematol.2026.s2.14111

P59 | BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES (64 Online Views)

D. Stoumbos1, A. Antoniou1, K. Lampropoulos1, S. Chrysoglou1, C. Prifti1, M. Panagiotouni1, M. Dadakaridou1, S. Giourgouli2, K. Stefanidis3, M. Kotsopoulou1

1 Metaxa Cancer Hospital, Hematology Clinic and Bone Marrow Transplantation Unit, Athens, Greece
2 Metaxa Cancer Hospital, Nuclear Medicine Department, Athens, Greece
3 Metaxa Cancer Hospital, Department of Radiology, Athens, Greece
Multiple Myeloma Elderly Bispecific antibodies
https://doi.org/10.3324/haematol.2026.s2.14044

P60 | TRIAL IN PROGRESS, MoMMent-3: A PROSPECTIVE, MULTINATIONAL, REAL-WORLD STUDY OF TALQUETAMAB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (78 Online Views)

K. Weisel1, E. Kastritis2, E. Gonzalez-Garcia3, S. Gentili4, C. Renner5, P. Ferraz6, N. Francella7, S. Sitar7, J. Buyze7, N. Healy7, N.M. Suñé7, P. Moreau8, M.V. Mateos9

1 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 National and Kapodistrian University of Athens, Greece
3 University Hospital Cabueñes, Gijón, Spain
4 UOSD Ematologia Civitanova Marche AST Macerata, Civitanova Marche, Italy
5 Klinik Hirslanden, Zurich, Switzerland
6 Unidade Local de Saúde de Trás-os-Montes e Alto Douro, Vila Real, Portugal
7 Johnson & Johnson Innovative Medicine
8 Hematology Clinic, University Hospital Hotel-Dieu, Nantes, France
9 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
LocoMMotion Trial MoMMent Trial Real-world Practice
https://doi.org/10.3324/haematol.2026.s2.14056

P61 | IMMUNE EFFECTOR CELL COLITIS DURING TREATMENT WITH AN ANTI-BCMA BISPECIFIC ANTIBODIES (78 Online Views)

M. Minnema1, H. Fidder2, R. Oostvogels1, V. Biemans2

1 Department of Hematology, UMC Utrecht, The Netherlands
2 Department of Gastroenterology, UMC Utrecht, The Netherlands
Multiple Myeloma Colitis Bispecific antibodies
https://doi.org/10.3324/haematol.2026.s2.14050

P62 | INITIAL EXPERIENCE WITH IDECABTAGENE VICLEUCEL IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA: CASE SERIES IN A TERTIARY CARE HOSPITAL (74 Online Views)

L. Piquer Monsonis1, A. Pérez Montaña1, J.M. Sánchez Raga1, A. Sampol Mayol1, M. Galí Sampol1, R. Ferrero Guillén1, E. Serrasoles Alemany1, M. Remezal Serrano1, A. Alonso Carballo1, S. Montolio Chiva1, P. Gómez Fernández1, J. Domínguez Esteve2, A. Horrillo Orejudo2

1 Department of Hematology and Hemotherapy, Hospital Universitari Son Espases, Palma de Mallorca, Spain
2 Hospital Comarcal de Inca, Spain
BCMA Decabtagene vicleucel Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14049
EMN 2026 - Session 4. Special conditions

P63 | TECLISTAMY (EMN40): A PHASE 2 TRIAL OF TECLISTAMAB IN PATIENTS WITH PREVIOUSLY TREATED LIGHT-CHAIN AL AMYLOIDOSIS (79 Online Views)

M. Roussel1, E. Kastritis2, S.O. Schönland3, K.M. Kortüm4, B. Arnulf5|6, A. Jaccard1, S. Vara7, M. Doyle7, J.M. Schecter7, A. Carpinteiro8, F. Kwok9, G. Palladini10|11, M.C. Minnema12, M. Boccadoro13, P. Sonneveld14|15

1 Hematology, Centre Hospitalier Universitaire Dupuytren, Limoges, France
2 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
3 Department of Internal Medicine V, Heidelberg University Hospital, Germany
4 Department of Internal Medicine II, University Hospital of Würzburg, Germany
5 Immuno-Hematology, Saint Louis Hospital, AP-HP, Paris, France
6 Université Paris Cité, France
7 Johnson & Johnson
8 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Germany
9 Department of Haematology, Westmead Hospital, Sydney, Australia
10 Department of Molecular Medicine, University of Pavia, Italy
11 Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
12 Department of Hematology, University Medical Center Utrecht, The Netherlands
13 European Myeloma Network, Italy
14 Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
15 European Myeloma Network, The Netherlands
AL amyloidosis TeclistAMY (EMN40) trial
https://doi.org/10.3324/haematol.2026.s2.14105

P64 | ODISSEY: A MULTICENTER, OBSERVATIONAL STUDY OF MULTIPLE MYELOMA ITALIAN PATIENTS WHO DISCONTINUED THERAPY IN CLINICAL PRACTICE (55 Online Views)

N. Sgherza1, E. Antonioli2, E. Zamagni3|4, C. Conticello5, F. Fazio6, S. Palmieri7, A. Cagnetta8, G. Palumbo9, A.G. Solimando10, R. Della Pepa11, C. Germano12, G. Palazzo13, C. De Risi14, A. Quinto15, G. Buda16, M. Gentile17|18, O. Annibali19, D. De Novellis20, P. Curci1, O. Battisti1, L. Pavan21|22, M. Capriata6, G. Di Carlo13, G. Proietti6, V. Del Fabro23, A.P. Falcone24, R. Spadano25, D. Derudas26, G. Mele27, G. Barilà28, M.T. Petrucci6, F. Di Raimondo5|29, F. Albano1|30, P. Musto1|30

1 Hematology and Stem Cell Transplantation Unit, AOUC Policlinico, Bari, Italy
2 Hematology Unit, Careggi University Hospital, Firenze, Italy
3 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli", Italy
4 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Italy
5 Division of Hematology and Stem Cell Transplantation, Policlinico“G. Rodolico-San Marco”, Catania, Italy
6 Department of Translational and Precision Medicine Hematology, Sapienza University, Roma, Italy
7 Hematology Unit, Ospedale Cardarelli, Napoli, Italy
8 Hematology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
9 Hematology Unit, AOU Policlinico Riuniti di Foggia, Italy
10 G. Baccelli Unit of Internal Medicine, Department of Precision and Regenerative Medicine and Ionian Area-(DiMePRe-J), School of Medicine, University of Bari Aldo Moro, Italy
11 Department of Clinical Medicine and Surgery, University Federico II, Napoli,Italy
12 Hematology Unit,“Mons. Dimiccoli” Hospital, Barletta, Italy
13 Hematology Unit, “G. Moscati” Hospital, Taranto, Italy
14 Haematology and Transplant Unit, “V. Fazzi” Hospital, Lecce, Italy
15 Hematology and Cell Therapy Unit, IRCCS “G. Paolo II”, Bari, Italy
16 Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Italy
17 Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Italy
18 Department of Pharmacy, Health and Nutritional Science, University of Calabria, Italy
19 Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Biomedico di Roma, Italy
20 Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy
21 Department of Medicine
22 (DIMED), Hematology section, Padua University School of Medicine, Italy
23 Faculty of Medicine and Surgery “Kore”, University of Enna, Italy
24 Department of Hematology and Bone Marrow Transplant, IRCSS Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy
25 Hematology Unit, Santo Spirito Hospital, Pescara, Italy
26 Department of Hematology, Businco Hospital, Cagliari, Italy
27 Hematology Unit,“A. Perrino” Hospital, Brindisi, Italy
28 Hematology Unit, Ospedale San Bortolo, Vicenza, Italy
29 Department of General Surgery and Medical-Surgical Specialties, Hematology Section, University of Catania, Italy
30 Department of Precision and Regenerative Medicine and Ionian Area, “Aldo Moro” University School of Medicine, Bari, Italy
Multiple Myeloma ODISSEY study Clinical Features
https://doi.org/10.3324/haematol.2026.s2.14114

P65 | FUNCTIONAL HIGH RISK MULTIPLE MYELOMA IN THE ANTI-CD38 QUADRUPLET ERA: REDEFINITION THROUGH REAL WORLD DATA (69 Online Views)

S. Morè1|2, M. Offidani2, L. Corvatta3, T. Za4, F. Fazio5, M. Gherardini5, V. Bongarzoni6, B. Anaclerico6, L. Franceschini7, S. Ferraro8, L. Cupelli8, R. Spadano9, L. De Padua10, A. Rago11, S. Gentili12, R. Latagliata13, M. Garzia14, I. Cordone15, V. Mezzanotte7, E. Rossi4, F. Di Landro4, Z. Limongi5, E. Morsia1, A. Poloni1, M.T. Petrucci5

1 Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica delle Marche, Ancona, Italy
2 Hematology Clinic, AOU delle Marche, Ancona, Italy
3 Internal Medicine, Ospedale E. Profili, Fabriano, Italy
4 Hematology Clinic, Policlinico Agostino Gemelli, Rome, Italy
5 Hematology Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University of Rome, Italy
6 Department of Hematology, San Giovanni-Addolorata Hospital, Rome, Italy
7 Lymphoproliferative Diseases Unit, Tor Vergata University Hospital, Rome, Italy
8 Hematology, Ospedale Sant’Eugenio, Rome, Italy
9 Hematology Unit, Pescara Hospital, Italy
10 UOC di Ematologia, Trapianto di Cellule Staminali e Terapia Genica, Frosinone, Italy
11 UOSD Ematologia ASL Roma1, Italy
12 UOSD Ematologia Civitanova Marche AST Macerata, Italy
13 UOC Hematology, Santa Rosa Hospital, Viterbo, Italy
14 Department of Hematology, Hematology San Camillo Forlanini Hospital, Rome, Italy
15 IRCCS Istituto Nazionale Tumori Regina Elena- Dipartimento di Ricerca, Diagnostica Avanzata ed Innovazione Tecnologica-IFO, Rome, Italy
Functional high-risk NDMM Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14070

P67 | TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS (73 Online Views)

T. Shragai1|2, M. Ganayem1, Y. Cohen1|2, I. Avivi1|2, E. Lebel3|4, N. Even-Gross Zohar3|4, N. Melamed1, M. Gatt3|4

1 Tel-Aviv Sourasky Medical Center, Israel
2 Tel-Aviv University, Israel
3 Hadassah Medical Center, Jerusalem, Israel
4 Hebrew University, Jerusalem, Israel
Multiple Myeloma AL amyloidosis Talquetamab
https://doi.org/10.3324/haematol.2026.s2.14072

P68 | BIOPSY SPECIFIC CHARACTERISTICS ARE IMPORTANT IN DETECTING AMYLOID IN PATIENTS WITH AMYLOIDOSIS (71 Online Views)

F.G. Weverling1, A. Vinkenborg1, R.J. Leguit2, M.C. Minnema1

1 Department of Hematology, University Medical Center Utrecht, The Netherlands
2 Department of Pathology, University Medical Center Utrecht, The Netherlands
AL amyloidosis Multiple Myeloma CR-staining
https://doi.org/10.3324/haematol.2026.s2.14088

P69 | REAL-WORLD USAGE OF HYALURONIDASE-FACILITATED SUBCUTANEOUS IMMUNOGLOBULIN 10% IN PATIENTS WITH MULTIPLE MYELOMA DIAGNOSED WITH SECONDARY IMMUNODEFICIENCY: AN INTERIM ANALYSIS (75 Online Views)

E. Kastritis1, S. Sánchez-Ramón2, A.G. Szabo3, B. Machalinski4, A. Pérez-Montaña5, J. Chen6, B. Mc Coy7, M. Kamieniak6, S. Wietek7

1 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Greece
2 Department of Clinical Immunology, Institute of Laboratory Medicine, Hospital Clínico San Carlos, Complutense University of Madrid, Spain
3 Department of Haematology, Rigshospitalet, University of Copenhagen, Denmark
4 Department of Hematology and Transplantology, Pomeranian Medical University, Szczecin, Poland
5 Hematology Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain
6 Takeda Development Center Americas, Inc, Cambridge, USA
7 Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
Multiple Myeloma HyMMy Trial Secondary immunodeficiency
https://doi.org/10.3324/haematol.2026.s2.14073

P70 | NOVEL MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE CARE PATHWAY FOR THE EARLY DETECTION OF M-PROTEIN RELATED DISEASES (61 Online Views)

M. Minnema1, F. Verheij1, J. Kortleve2, K. Aarsman1, R. Blommers2, R. Oostvogels1, P. Westerweel2

1 Department of Hematology, UMC Utrecht, The Netherlands
2 Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands
MGUS Al Amyloidosis Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14079

P71 | DARATUMUMAB IN PATIENTS WITH AL AMYLOIDOSIS: A PORTUGUESE MULTICENTER REAL-WORLD STUDY (52 Online Views)

R. Bergantim1, A. Roque2, J. Vieira3, G. Ferreira4, P. Martins Almeida3, P. Ferraz5, J. G. Freitas6, M. Neves7, E. Aguiar1, M. Lopes8, H. Martins3, F. Trigo1, C. Geraldes2, C. João7

1 ULS São João, Porto, Portugal
2 ULS Coimbra, Portugal
3 ULS Santa Maria, Lisboa, Portugal
4 ULS Aveiro, Portugal
5 ULS TMAD, Vila Real, Portugal
6 ULS Braga, Portugal
7 Fundação Champalimaud, Lisboa, Portugal
8 ULS EDV, Santa Maria da Feira, Portugal
AL amyloidosis Multiple Myeloma Real-world Study
https://doi.org/10.3324/haematol.2026.s2.14098

P72 | BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY AL AMYLOIDOSIS: CLINICAL EXPERIENCE IN TWO ACADEMIC BELGIAN CENTERS (59 Online Views)

M.C. Vekemans1, O. Rizzo2, N. Meuleman2

1 Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Bruxelles, Belgium
2 Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Belgium
AL Amyloidosis Multiple Myeloma anti-BCMA
https://doi.org/10.3324/haematol.2026.s2.14109

P73 | TP53 MUTATION AND MSS-WM IDENTIFY HIGH RISK WALDENSTRÖM MACROGLOBULINEMIA IN A REAL WORLD COHORT (84 Online Views)

U. Calis1, S. Yuksel2, M. K. Yuksel1, P. Topcuoglu1, I. Kuzu2, O. Arslan1, M. Ozcan1, T. Demirer1, S. Kocak Toprak1, M. Beksac3, G. Cengiz Seval1

1 Department of Hematology, Ankara University Faculty of Medicine, Turkey
2 Department of Pathology, Ankara University Faculty of Medicine, Turkey
3 Department of Hematology Istinye University, Ankara Liv Hospital, Turkey
Waldenström macroglobulinemia Real-world Practice
https://doi.org/10.3324/haematol.2026.s2.14096

P74 | AUTOMATED PANEL-AGNOSTIC FLOW CYTOMETRIC MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA USING QUALITY CONTROL-AWARE MACHINE LEARNING (65 Online Views)

E. Akar1, M. Baysal1, S. Cakmak1, S. Akpinar1, B. Turgut1

1 Hematology Department, Tekirdag Namik Kemal University Hospital, Turkey
Multiple Myeloma Minimal residual disease Quality Control
https://doi.org/10.3324/haematol.2026.s2.14062

P75 | CURRENT STATUS OF REGISTRY OF MONOCLONAL GAMMOPATHIES - THE CZECH MYELOMA GROUP "REAL WORLD“ DATABASE (59 Online Views)

V. Maisnar1, L. Pour2, I. Spicka3, J. Minarik4, T. Jelinek5, A. Jungova6, P. Pavlicek7, L. Roziakova8, J. Radocha1, A. Heindorfer9, M. Sykora10, P. Kessler11, L. Stejskal12, M. Wrobel13, J. Kopeckova14, K. Stankova15, L. Pospisilova15, R. Hajek5

1 4th Department of Medicine - Hematology, University Hospital, Hradec Kralove, Czech Republic
2 Internal Hemato-Oncology Clinic, University Hospital, Brno, Czech Republic
3 1st Medical Department – Clinical Department of Haematology, General Teaching Hospital, Prague, Czech Republic
4 Department of Hematooncology, University Hospital, Olomouc, Czech Republic
5 Department of Clinical Hematology, University Hospital, Ostrava, Czech Republic
6 Department of Hemato-oncology, University Hospital, Plzen, Czech Republic
7 Department of Clinical Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic
8 Department of Clinical Hematology, University Hospital, Bratislava, Slovakia
9 Department of Hematology, Regional Hospital, Liberec, Czech Republic
10 Department of Clinical Hematology, Regional Hospital, Ceske Budejovice, Czech Republic
11 Department of Hematology, Regional Hospital, Pelhrimov, Czech Republic
12 Department of Hematology and Transfusion, Silesian Regional Hospital, Opava, Czech Republic
13 Department of Oncology, Regional Hospital, Novy Jicin, Czech Republic
14 Czech Myeloma Group, Brno, Czech Republic
15 Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
Real-world Practice Monoclonal Gammopathies RMG Working Group
https://doi.org/10.3324/haematol.2026.s2.14102

P76 | DIFFERENT OUTCOMES OF t(11;14) MULTIPLE MYELOMA AND THERAPY-RELATED ACUTE UNDIFFERENTIATED LEUKEMIA TO VENETOCLAX-BASED THERAPY AND ALLOGENEIC STEM CELL TRANSPLANTATION (75 Online Views)

V. Latal1, A. Kuba1, T. Pika1, M. Novak1, J. Balcarkova1, J. Navratilova1, M. Cernan1, T. Szotkowski1, J. Minarik1, T. Papajik1

1 Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
Multiple Myeloma Secondary malignancies Follow-up
https://doi.org/10.3324/haematol.2026.s2.14077

P77 | LIGHT CHAIN DEPOSITION DISEASE: A RARE CAUSE OF RENAL INJURY WITH EMERGING THERAPEUTIC OPTIONS (77 Online Views)

R. Cassano Cassano1|2, S. Galimberti3, A.G. Bonadio4, L.M.A. Melillo5, D. Giannese6, G. Buda3

1 University of Foggia, Italy
2 University of Washington, Fred Hutchinson Cancer Center, Seattle, USA
3 Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Italy
4 Department of Surgical, Medical, Molecular Pathology and Critical Area, Division of Surgical Pathology II, University of Pisa, Italy
5 Hematology, Riuniti Hospital, Foggia, Italy
6 Department of Clinical and Experimental Medicine, Nephrology Unit, University of Pisa, Italy
Light chain deposition disease Renal Impairment Multiple Myeloma
https://doi.org/10.3324/haematol.2026.s2.14099
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online